ORGAN SPECIFIC IMMUNOSUPRESSION

器官特异性免疫抑制

• 批准号: 6294440
• 负责人: Lauren Brasile
• 金额: $ 10万
• 依托单位: BREONICS, INC.
• 依托单位国家: 美国
• 财政年份: 2001
• 资助国家: 美国
• 起止时间: 2001-09-15 至 2002-03-14
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6294440
• 关键词: artificial immunosuppression; biomaterial development /preparation; biomaterial evaluation; biotechnology; dogs; immunomodulators; kidney transplantation; tissue /organ preservation; transplant rejection

DESCRIPTION: BREONICS is developing ENDOMATRIX, a natural, matrix membrane, capable of serving as an immunomodifying agent rendering allografts nonimmunogenic and nonthrombogenic on an organ-specific basis. Previous studies indicated that ENDOMATRIX has the potential to inhibit allorecognition by interrupting the interface between donor endothelium and recipient immunocompetent cells. Since our last submission, studies have been completed defining the dose and application method for applying the immunomodifying therapy to canine kidneys. The ENDOMATRIX therapy was administered via a new organ preservation technology called Exsanguinous Metabolic Support (EMS) being developed by BREONICS with our collaborative partner Hospital Products Division Abbott Laboratories. Based upon these results, canine autotransplantation studies have been completed that demonstrate the ability to coat the vascular lumen within an intact organ. These studies demonstrate that ENDOMATRIX therapy did not adversely affect kidney function. We are requesting funding to perform a feasibility study to evaluate the efficacy of ENDOMATRIX therapy in preventing allograft rejection. The proposed study will use a canine allo-transplantation model and compare graft outcomes in two test groups of ENDOMATRIX treated kidneys to control animals given standard immunosuppression. The successful development of ENDOMATR1X therapy could potentially diminish the incidence of chronic graft rejection by preventing allosensitization and eliminate the systemic toxicity associated with traditional immunosuppressive regimens. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE

描述：BREONICS正在开发ENDOMATRIX，一种天然基质膜， 能够作为免疫调节剂使同种异体移植物 在器官特异性的基础上无免疫原性和无血栓形成。以前的研究 表明ENDOMATRIX具有抑制同种异体识别的潜力， 中断供体内皮和受体之间的界面 免疫活性细胞自我们上次提交以来， 确定应用免疫调节的剂量和应用方法， 治疗犬肾的方法ENDOMATRIX治疗通过一种新的 器官保存技术称为失血性代谢支持（EMS）， 由BREONICS与我们的合作伙伴医院产品部共同开发 雅培实验室。根据这些结果，犬自体移植 已经完成的研究表明， 完整器官内的管腔。这些研究表明， 对肾功能没有不良影响。我们正在申请资金 评价ENDOMATRIX治疗在以下患者中的疗效的可行性研究 防止同种异体移植排斥。这项拟议中的研究将使用一只狗 同种异体移植模型，并比较两个试验组的移植结果， ENDOMATRIX处理的肾脏与给予标准免疫抑制的对照动物。 ENDOMATR1X疗法的成功开发可能会减少 通过预防同种异体致敏和 消除与传统免疫抑制剂相关的全身毒性， 养生法 拟议商业应用：不可用

项目成果

Pretransplant kidney-specific treatment to eliminate the need for systemic immunosuppression.

• DOI: 10.1097/tp.0b013e3181ffba97
• 发表时间: 2010-12-27
• 期刊: Transplantation
• 影响因子: 6.2
• 作者: Brasile L;Glowacki P;Castracane J;Stubenitsky BM
• 通讯作者: Stubenitsky BM